Seladelpar Reduces Serum IL-31, Improves Pruritus in Patient

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.

Related Keywords

Zurich , Züsz , Switzerland , Researchgate Andreas Kremer , Cymabay Seladelpar , Drug Administration , University Hospital Zurich , Andreas Kremer , Bay Therapeutics , Breakthrough Therapy Designation , New Drug Application , Priority Review , Pruritis Improvement , Primary Biliary Cholangitis , Hoc Analysis , Primary Biliary , Cpbc , Pruritus , Interleukin 31 , Il 31 , Bile Acid , Seladelpar ,